AUSTRALIAN CLINICAL LABS LIMITED (ACL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ACL - AUSTRALIAN CLINICAL LABS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.77
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.62

30 Nov
2023

0.030

OPEN

$2.58

1.16%

HIGH

$2.62

706,832

LOW

$2.55

TARGET
$3.367 28.5% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
AHX . ALC . BMT . CAJ . DOC . EBO . HLA . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
ACL: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 17.9 18.0 xxx
DPS (cps) xxx 14.0 13.2 xxx
EPS Growth xxx - 79.8% 0.7% xxx
DPS Growth xxx - 73.6% - 6.0% xxx
PE Ratio xxx N/A 14.1 xxx
Dividend Yield xxx N/A 5.2% xxx
Div Pay Ratio(%) xxx 78.2% 73.0% xxx

Dividend yield today if purchased 3 years ago: 1,400.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 5.49

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 14/09 - ex-div 7c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 20192020202120222023
EPS Basic xxxxxxxxxxxx17.9
DPS All xxxxxxxxxxxx14.0
Sales/Revenue xxxxxxxxxxxx692.1 M
Book Value Per Share xxxxxxxxxxxx86.0
Net Operating Cash Flow xxxxxxxxxxxx143.7 M
Net Profit Margin xxxxxxxxxxxx5.19 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20192020202120222023
Return on Capital Employed xxxxxxxxxxxx17.73 %
Return on Invested Capital xxxxxxxxxxxx9.12 %
Return on Assets xxxxxxxxxxxx5.95 %
Return on Equity xxxxxxxxxxxx17.73 %
Return on Total Capital xxxxxxxxxxxx11.40 %
Free Cash Flow ex dividends xxxxxxxxxxxx39.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20192020202120222023
Short-Term Debt xxxxxxxxxxxx101 M
Long Term Debt xxxxxxxxxxxx215 M
Total Debt xxxxxxxxxxxx316 M
Goodwill - Gross xxxxxxxxxxxx159 M
Cash & Equivalents - Generic xxxxxxxxxxxx21 M
Price To Book Value xxxxxxxxxxxx4.00

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20192020202120222023
Capex xxxxxxxxxxxx6.9 M
Capex % of Sales xxxxxxxxxxxx1.00 %
Cost of Goods Sold xxxxxxxxxxxx546 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx90 M
Research & Development xxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

13/09/2023

3

Initiation of coverage with Neutral

$3.00

14.50%

Macquarie initiates coverage on Australian Clinical Labs with a Neutral rating and $3.20 target. The broker expects a recovery in pathology over the medium to longer term although subdued GP volumes are constraint in the near term.

Data has shown improved trends recently yet volumes are still below trend. For FY24/25 Macquarie forecasts industry growth of 5%.

With less favourable industry dynamics compared with diagnostic imaging and multiples above average the broker awaits signs of a recovery in GP consultations before becoming more positive.

FORECAST
Macquarie forecasts a full year FY24 dividend of 12.00 cents and EPS of 17.50 cents.
Macquarie forecasts a full year FY25 dividend of 15.00 cents and EPS of 21.60 cents.

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

ACL STOCK CHART

FNArena News on ACL

1
Rudi’s View: Outlook Negative, With Plenty Of Silver Linings

Sep 06 2023 - Rudi's View
2
Australian Broker Call *Extra* Edition – Aug 24, 2023

Aug 24 2023 - Daily Market Reports
3
FNArena Corporate Results Monitor – 23-08-2023

Aug 23 2023 - Australia
4
Rudi’s View: Awaiting The August Verdict

Aug 02 2023 - Rudi's View
5
Australian Broker Call *Extra* Edition – Jul 25, 2023

Jul 25 2023 - Daily Market Reports

Latest Healthcare services News

1
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
2
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
3
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
4
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
5
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
6
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
7
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
8
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
9
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
10
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals